CYP17A1 and prostate cancer: In conclusion,there is still a need for improved compounds as potent and selectiveinhibitors of the steroidogenic CYP17A1 enzyme as a target for treatmentof serious hormone-dependent cancer diseases, e.g., prostate cancer.The extensive work in recent years has provided compounds, belongingto the non-steroidal class, with improved activity and selectivityas well as translational properties.